½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting

  • »¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

    021-54845833/15800441009

    Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

    µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ϸ°ûϵ > ÈËϸ°ûϵ > MDA-MB-468ÈËÈéÏÙ°©Ï¸°û(L15)

    ²úÆ·ÖÐÐÄ

    • MDA-MB-468ÈËÈéÏÙ°©Ï¸°û(L15)

      ¹æ¸ñ£º
      ¼Û¸ñ£º£¤
      • Æ·ÅÆ : ͨεÉúÎï
      • Ŀ¼ºÅ : TW35337
      • Ó¦Óà : ½ö¹©¿ÆÑÐʹÓÃ
      • »õÆÚ : ÏÖ»õ
      • ¹æ¸ñ £º1¡Á10?cells
    • ÉÌÆ·ÏêÇé
    • ²Î¿¼ÎÄÏ×
    • ˵Ã÷ÊéÏÂÔØ
    • ÉÌÆ·ÆÀÂÛ0
    • Ïà¹Ø²úÆ·
    »ù±¾ÐÅÏ¢
    ²úÆ·Æ·ÅÆ £º ͨεÉúÎï
    ÖÐÎÄÃû³Æ £º ÈËÈéÏÙ°©Ï¸°û
    ϸ°û¼ò³Æ £º M DA-M B -468
    ϸ°û±ð³Æ £º MDA-MB 468; MDA-MB468; MDAMB468; MDA-468; MDA468; MB468;MD Anderson-Metastatic Breast-468
    ϸ°ûÐÎ̬ £º ÉÏÆ¤Ï¸°ûÑù
    Éú³¤ÌØÐÔ £º Ìù±Úϸ°û
    ÅàÑø»·¾³ £º ¿ÕÆø£¬100% 37¡æ
    ¶³´æÌõ¼þ £º 55% »ù´¡ÅàÑø»ù+40% FBS+5% D M SOÒºµª
    ÍêÈ«ÅàÑø»ù£ºLeibovitz's L-15(PM151010)£«10% FBS(164210-50)£«1% P/S(PB180120)

    ´«´ú²½Öè
    1¡¢Îü³öÔ­ÅàÑøÒº¡£
    2¡¢¼ÓÈë2ml×óÓÒPBS£¬ÇáÇá»Î¶¯ÅàÑøÆ¿Èóϴϸ°û,Îü³öPBS¶ªÆú¡£
    3¡¢¼ÓÈë1ml×óÓÒ0.25% Òȵ°°×øÈÜÒº£¨º¬ED TA £©£¬ÇáÇá»Î¶¯ÅàÑøÆ¿Ê¹Ö®½þÈóËùÓÐϸ°û¡£
    4¡¢·ÅÈëÅàÑøÏäÏû»¯£¬ÏÔ΢¾µÏ¿´µ½Ï¸°û¿éÖмäµÄϸ°ûÃ÷ÏÔ±äÔ²Óмä϶ʱ¿ÉÖÕÖ¹£¬È«³Ì²»ÒªÅÄ´òÅàÑøÆ¿¡£
    5¡¢¼ÓÈë3mlº¬ÑªÇåµÄÅàÑø»ùÖÕÖ¹Ïû»¯£¬´µ´òϸ°ûʹ֮Íѱڲ¢ÔÚÒºÌåÀï·´¸´´µ´òʹϸ°û¾¡Á¿³Êµ¥¿Åϸ°ûµÄÐü¸¡Òº¡£
    6¡¢ÊÕ¼¯Ï¸°ûÐüÒºÀëÐÄ£¬1200rpm /min 3·ÖÖÓ£¬ÀëÐÄÍêÎü³öÉÏÇ嶪Æú¡£
    7¡¢¼ÓÈëÐÂÏÊÅàÑø»ù£¬´µ´ò¼¸Ï»ìÔÈϸ°û¼´¿É£¬°´±ÈÀý½ÓÖÖµ½ÐÂÅàÑøÆ¿£¬²¹×ãÅàÑø»ù£¬Å¡ËÉÆ¿¸Ç»òʹÓÃÍ¸ÆøÆ¿¸Ç½øÐÐÅàÑø¡£
    Ïû»¯Ê±¼ä £º 2~ 3·ÖÖÓ
    ´«´ú±ÈÀý£¨Ãܶȣ© £º 1:2-1:4
    »»ÒºÆµ´Î £º 2~ 3´Î/ÖÜ

    ϸ°û±³¾°ÃèÊö
    MDA-MB-468ϸ°ûÊÇÓÉCailleau¡¤RµÈÈËÓÚ1977Äê´Óһλ»¼ÓÐ×ªÒÆÐÔÈéÏÙ°©µÄ51ËêºÚÈËÅ®ÐÔµÄÐØÇ»»ýÒºÖзÖÀëµÃµ½µÄ¡£ËäÈ»¹©Ìå×éÖ¯µÄG6PDµÈλ»ùÒòÔӺϣ¬µ«MDA-MB-468ϸ°ûʼÖÕ±íÏÖΪG6PD A±íÐÍ¡£p53MDA-MB-468ϸ°ûÊÇÓÉCailleau¡¤RµÈÈËÓÚ1977Äê´Óһλ»¼ÓÐ×ªÒÆÐÔÈéÏÙ°©µÄ51ËêºÚÈËÅ®ÐÔµÄÐØÇ»»ýÒºÖзÖÀëµÃµ½µÄ¡£ËäÈ»¹©Ìå×éÖ¯µÄG6PDµÈλ»ùÒòÔӺϣ¬µ«MDA-MB-468ϸ°ûʼÖÕ±íÏÖΪG6PD A±íÐÍ¡£p53»ùÒò273λÃÜÂë×Ó´æÔÚG¡úAÍ»±ä£¬´Ó¶øµ¼ÖÂArg¡úHisÌæ´ú¡£Ã¿¸öMDA-MB-468ϸ°ûÉÏ´æÔÚ1¡Á10^6¸öEGFÊÜÌå¡£
    ±¶Ôöʱ¼ä £º ~36-62Сʱ
    ¹©ÌåÄêÁä £º Å®ÐÔ£¬51Ëê
    ×éÖ¯À´Ô´ £º ÈéÏÙ£»Èé·¿£»ÏÙ°©
    ϸ°ûÀàÐÍ £º Ö×Áöϸ°û
    Ö×ÁöÀàÐÍ £º ÈéÏÙ°©Ï¸°û
    ÉúÎﰲȫµÈ¼¶ £º 1
    ÖÂÁöÐÔ £º Yes, in nude mice inoculated subcutaneously with 1¡Á10^7 cells.(Tumorsdeveloped within 21 days at 100% frequency (5/5).)
    ÊÜÌå±í´ï £º epidermal growth factor (EGF); transforming growth factor alpha (TGFalpha)
    ¿¹Ô­±í´ï £º Blood Type AB; HLA Aw23, Aw30, B27, Bw35, Cw2, Cw4 (patient)
    ϸ°û±£²ØÖÐÐÄ £º ATCC; HTB-132 DSMZ; ACC-738

    ÊÕµ½³£ÎÂϸ°ûºóÈçºÎ´¦Àí
    ϸ°ûÅàÑøÏêϸ²Ù×÷²½ÖèÇë²ÎÕÕͨεÉúÎïϸ°ûÅàÑø²Ù×÷Ö¸ÄÏ
    1.ÊÕµ½³£ÎÂϸ°ûºó£¬¼°Ê±ÅÄÕռǼÓÐÎÞ©Һ/Æ¿ÉíÆÆËðÏÖÏó¡£
    2.ÓÃ75%¾Æ¾«²ÁÊÃϸ°ûÅàÑøÆ¿±íÃæ£¬ÏÔ΢¾µÏ¹۲ìϸ°û״̬¡£ÏȲ»Òª´ò¿ªÅàÑøÆ¿¸Ç£¬½«Ï¸°ûÖÃÓÚϸ°ûÅàÑøÏäÄÚ¾²ÖÃÅàÑø2-4Сʱ£¬ÒÔ±ãÎȶ¨Ï¸°û״̬¡£
    3.×ÐϸÔĶÁϸ°û˵Ã÷Ê飬Á˽âϸ°ûÏà¹ØÐÅÏ¢£¬ÈçÌù±ÚÌØÐÔ£¨Ìù±Ú/Ðü¸¡£©¡¢Ï¸°ûÐÎ̬¡¢ËùÓûù´¡ÅàÑø»ù¡¢ÑªÇå±ÈÀý¡¢ËùÐèϸ°ûÒò×Ó¡¢´«´ú±ÈÀý¡¢»»ÒºÆµÂʵÈ¡£
    4.¾²ÖÃÍê³Éºó£¬È¡³öϸ°ûÅàÑøÆ¿£¬¾µ¼ì¡¢ÅÄÕÕ£¬¼Ç¼ϸ°û״̬£¨ËùÅÄÕÕÆ¬ ½«×÷ΪºóÐø·þÎñÒÀ¾Ý£©£»½¨Òéϸ°û´«´úÅàÑøºó£¬¶¨ÆÚÅÄÕÕ¡¢¼Ç¼ϸ°ûÉú³¤×´Ì¬¡£
    5.Èô¹Û²ìµ½Òì³£»òÕß¶Ôϸ°ûÓÐÒÉÎÊ£¬Ç뼰ʱ¸úÎÒÃÇÁªÏµ£»¶ÔÓÚϸ°ûÅàÑø²Ù×÷¼°ÅàÑø¡£¿É¸úÎÒÃǵļ¼ÊõÖ§³Ö½»Á÷¡£

    ÊÛǰÐëÖª
    1¡¢¸Ãϸ°ûÍÆ¼öʹÓÃLeibovitz's L-15ÅàÑø»ù½øÐÐÅàÑø£¬Leibovitz's L-15²»¿ÉÒÔͨÈë¶þÑõ»¯Ì¼£¬»á²úÉúϸ°û¶¾ÐÔ£» 2¡¢ÈçÄúûÓÐÎÞ¶þÑõ»¯Ì¼µÄÅàÑøÏ䣬¿ÉʹÓÃDMEMÌæ´úLeibovitz's L-15£¬Ê¹ÓÃDMEMÅàÑø»ùʱ¼´¿ÉÕý³£Í¨Èë5%¶þÑõ»¯Ì¼¡£
    3¡¢ÅäÌ×רÓÃÅàÑø»ùĬÈÏLeibovitz's L-15ÅäÖã¬ÈçÐèDMEMÅä·½£¬ÇëÁªÏµÏúÊÛϵ¥±¸×¢¸ü¸Ä¡£
    4¡¢¸Ãϸ°ûÅàÑø¹ý³ÌÖлá·ÖÃÚÉÙÁ¿ºÚÉ«¿ÅÁ£Î²»Ó°Ïìϸ°ûÉú³¤£¬ÊôÕý³£ÏÖÏó¡£
    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿